Kainate GluK1 receptor neurons (also called GluK1-positive neurons or KAR1 neurons) are neurons that express functional kainate-type ionotropic glutamate receptors containing the GluK1 subunit (formerly known as GluR5 or KAR1). These neurons represent a specialized population of glutamatergic neurons in which kainate receptors play a critical role in modulating synaptic transmission, neuronal excitability, and network oscillations throughout the central nervous system.
| Property |
Value |
| Category |
Ionotropic glutamate receptor neurons |
| Neurotransmitter |
Glutamate |
| Receptor Type |
Ionotropic kainate receptor (iGluR) |
| Receptor Subunit |
GluK1 (formerly GluR5, KAR1) |
| Primary Brain Regions |
Hippocampus, cerebral cortex, amygdala, cerebellum, spinal cord |
| Gene |
GRIK1 (Glutamate Ionotropic Kainate Receptor Subunit 1) |
¶ Molecular Biology and Receptor Structure
¶ GluK1 Gene and Protein
The GRIK1 gene (also known as GLUR5 or KAR1) encodes the GluK1 protein subunit, one of five subunits (GluK1-5) that form functional kainate receptors. The GRIK1 gene is located on chromosome 21q21.1 in humans and is expressed predominantly in neurons, with lower expression in astrocytes and oligodendrocytes.
The GluK1 protein has several key structural features:
- N-terminal domain (ATD): Involved in subunit assembly and receptor trafficking
- Ligand-binding domain (LBD): Binds glutamate and related agonists (kainic acid, domoic acid)
- Transmembrane domain (TMD): Forms the ion channel pore
- C-terminal domain (CTD): Involved in protein-protein interactions and synaptic anchoring
Functional kainate receptors can assemble as:
- Homomeric receptors: Five GluK1 subunits forming the channel
- Heteromeric receptors: GluK1 co-assembling with GluK2 (GRIK2), GluK3 (GRIK3), GluK4 (GRIK4), or GluK5 (GRIK5)
The stoichiometry affects channel properties, including conductance, kinetics, and pharmacological profile.
¶ Anatomy and Distribution
GluK1-expressing neurons are found in multiple brain regions:
Hippocampus:
- CA1 and CA3 pyramidal neurons (presynaptic and postsynaptic)
- Dentate gyrus granule cells
- Various interneuron subtypes
- Mossy fiber terminals
Cerebral Cortex:
- Layer 2/3 pyramidal neurons
- Layer 5 pyramidal neurons
- Cortical interneurons (various subtypes)
Amygdala:
- Principal neurons in basolateral amygdala
- Various interneuron populations
Cerebellum:
- Purkinje cells
- Granule cells
- Molecular layer interneurons
Spinal Cord:
- Dorsal horn neurons (laminae I-II)
- Motor neurons
GluK1 receptors exhibit both presynaptic and postsynaptic localization:
- Presynaptic: On axon terminals modulating neurotransmitter release
- Postsynaptic: On dendritic spines and shafts mediating excitatory responses
- Extrasynaptic: Contributing to tonic glutamate signaling
¶ Physiology and Function
GluK1-containing kainate receptors are ion channels that conduct sodium (Na⁺) and potassium (K⁺) ions, with some permeability to calcium (Ca²⁺):
- Single-channel conductance: 1-10 pS
- Activation time: 1-5 ms
- Desensitization time: 100-1000 ms
- Deactivation time: 10-100 ms
Kainate receptors play complex roles in synaptic transmission:
Presynaptic Modulation:
- Regulate glutamate release probability
- Facilitate or depress transmission depending on brain region
- Modulate short-term plasticity
Postsynaptic Responses:
- Contribute to excitatory postsynaptic potentials (EPSPs)
- Shape synaptic integration
- Participate in coincidence detection
GluK1 receptors contribute to various brain oscillations:
- Theta oscillations (4-8 Hz): Important for memory consolidation
- Gamma oscillations (30-80 Hz): Involved in cognitive processing
- Sharp-wave ripples: Critical for memory replay
GRIK1 expression follows a developmental pattern:
- Embryonic: Low expression in developing brain
- Postnatal: Increased expression during first two weeks (rodent)
- Adult: Stable expression with regional variations
- Aging: Changes in expression associated with cognitive decline
GluK1 receptors participate in:
- Synaptogenesis: Formation and refinement of synaptic connections
- Neuronal migration: Activity-dependent guidance
- Circuit maturation: Activity-dependent refinement
GluK1 receptor neurons are implicated in Alzheimer's disease pathophysiology:
- Excitotoxicity: Enhanced GluK1 signaling may contribute to excitotoxic neuronal death
- Amyloid interaction: Aβ oligomers can modulate kainate receptor function
- Tau pathology: Tau affects GluK1 receptor trafficking and function
- Memory deficits: Altered synaptic plasticity mediated by GluK1 receptors
- Therapeutic potential: GluK1 antagonists may provide neuroprotection
Research findings:
- GluK1 expression is altered in AD brain tissue
- Kainate receptors modulate Aβ-induced toxicity
- Genetic variants in GRIK1 may influence AD risk
GluK1 receptors play complex roles in PD:
- Basal ganglia circuitry: Modulate indirect pathway activity
- Excitotoxicity: Contributing to dopaminergic neuron death
- L-DOPA-induced dyskinesia: GluK1 antagonists may reduce dyskinesias
- Neuroinflammation: Interactions with glial cells
In ALS:
- Motor neuron vulnerability: Altered GluK1 expression in motor neurons
- Excitotoxicity: Enhanced kainate receptor-mediated toxicity
- Glutamate transport: Interactions with excitatory amino acid transporters
GluK1 receptors have a well-established role in epilepsy:
- Seizure initiation: GluK1 agonists (kainic acid) induce seizures
- Seizure susceptibility: Genetic variants in GRIK1 affect seizure threshold
- Temporal lobe epilepsy: Altered GluK1 expression in hippocampus
- Therapeutic targeting: GluK1 antagonists as antiepileptic agents
In pain pathways:
- Spinal cord: GluK1 receptors in dorsal horn mediate pain transmission
- Peripheral sensitization: Upregulation of GluK1 in chronic pain states
- Analgesic potential: GluK1 antagonists show analgesic effects in animal models
GluK1 is implicated in:
- Depression: Altered GluK1 signaling in mood disorders
- Anxiety: Modulation of amygdala circuits
- Schizophrenia: Genetic associations with GRIK1
- Autism spectrum disorders: Possible developmental roles
GluK1 receptors are therapeutic targets for:
- Antiepileptic drugs: Novel GluK1 antagonists in development
- Analgesics: Peripherally-acting GluK1 antagonists for neuropathic pain
- Neuroprotective agents: GluK1 modulation in AD and PD
- Antidepressants: GluK1-based approaches for mood disorders
¶ Agonists and Antagonists
- Agonists: Kainic acid, domoic acid, ATPA (amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
- Antagonists: LY466365, UBP310, ACET, NS3763
- Viral vector delivery of GRIK1 modulators
- CRISPR-based approaches for GRIK1 editing
- RNA interference for downregulation
- Electrophysiology: Patch-clamp recordings of GluK1 currents
- Molecular biology: siRNA knockdown, CRISPR editing
- Histology: Immunohistochemistry for GluK1 protein
- Behavior: Genetic models, pharmacological manipulation
- Imaging: Calcium imaging, two-photon microscopy
- GRIK1 knockout mice
- Transgenic mice with human GRIK1
- Kainic acid-induced seizure models
- Genetic models of AD, PD, and ALS
- Contractor A, et al. Kainate receptors come of age. Neuron. 2011
- Lerma J, et al. Kainate receptor physiology. Trends Neurosci. 2014
- Pinheiro P, et al. Role of kainate receptors in the hippocampus. Curr Opin Neurobiol. 2013
- Jane DE, et al. Pharmacology of ionotropic glutamate receptors. Neuropharmacology. 2009
- Bortolotto ZA, et al. Kainate receptors and synaptic plasticity. Neuropharmacology. 2017
- Melyan Z, et al. Regulation of synaptic transmission by kainate receptors. J Physiol. 2010
- Kieval JZ, et al. Kainate receptors and epilepsy. Epilepsy Curr. 2001
- Rogawski MA. Kainate receptors and seizures. Prog Brain Res. 1998
- Cai X, et al. GluK1 receptors in neuropathic pain. Eur J Pharmacol. 2018
- Li W, et al. Kainate receptors in Alzheimer's disease. J Alzheimers Dis. 2020
Kainate receptors, including GluK1-containing receptors, have distinct pharmacological profiles:
Endogenous Agonists:
- Glutamate: Primary endogenous ligand
- Kainic acid: Naturally occurring toxin from algae
- Domonic acid: Marine neurotoxin
Synthetic Agonists:
- ATPA: (2S,4R)-4-Phosphonomethyl-2-pyrrolidineacetic acid
- LY382884: Selective GluK1 antagonist
Selective Agonists:
- Kainic acid: High-affinity agonist
- Willardiine: Partial agonist
Competitive Antagonists:
- CNQX: AMPA/Kainate antagonist
- DNQX: Non-selective iGluR antagonist
- NBQX: Water-soluble antagonist
- LY466365: GluK1-selective antagonist
Non-competitive Antagonists:
- Conantokins: Peptide antagonists from cone snails
- LY425465: Antagonist with neuroprotective properties
The GluK1 receptor channel exhibits:
- Single channel conductance: 0.8-3 pS
- Mean open time: 1-5 ms
- Mean closed time: 10-100 ms
- Desensitization rate: 100-500 ms
- Recovery from desensitization: 1-10 s
- Sodium (Na+): Primary permeant ion
- Potassium (K+): Permeant, contributes to currents
- Calcium (Ca2+): Low permeability (~1% of Na+)
- Chloride (Cl-): Impermeant
GluK1 orthologs are conserved across vertebrates:
- Mammals: GRIK1 widely expressed
- Birds: Avian GRIK1 homologs
- Fish: Multiple kainate receptor subtypes
- Reptiles: Primitive kainate receptor forms
- Amphibians: Amphibian-specific isoforms
The kainate receptor family evolved from:
- Ionotropic glutamate receptor ancestors
- Early tetrapod expansions
- Mammalian diversification
GluK1 expression has potential as:
- Diagnostic marker: Brain region-specific expression
- Prognostic marker: Disease progression
- Therapeutic target: Drug development
- Research biomarker: Receptor availability
- Radioligand binding: [3H]kainic acid
- Immunohistochemistry: Anti-GluK1 antibodies
- mRNA quantification: PCR methods
- PET ligands: Emerging imaging agents
¶ Ethics and Research
Research on GluK1 requires:
- Ethical considerations: Pain and distress management
- Reduction: Minimizing animal numbers
- Refinement: Improving procedures
- Alternatives: In vitro models when possible
Human studies involve:
- Genetic associations: GRIK1 variants
- Postmortem studies: Brain tissue analysis
- Imaging studies: PET ligand development
- Clinical trials: Therapeutic agents
This page was expanded on 2026-03-09 to provide comprehensive coverage of GluK1 receptor neurons including molecular biology, anatomy, physiology, disease involvement, and therapeutic implications.